Business Segments Protagonist Therapeutics, Inc.
Equities
PTGX
US74366E1029
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.48 USD | -1.70% |
|
+4.68% | +43.73% |
| 07-07 | Protagonist Therapeutics, Inc. - Special Call | |
| 06-17 | Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology (Startups) | 28.63M | 27.36M | 26.58M | 60M | 434M | |||||
Total Assets | 324M | 348M | 248M | 358M | 745M | |||||
Interest Expense | -598K | - | - | - | - | |||||
Income Tax Expense | 1.3M | - | - | - | 4.22M | |||||
CAPEX | -471K | -1.1M | -795K | -609K | -1.36M | |||||
EBT | -64.84M | -126M | -127M | -78.96M | 279M | |||||
D&A | 2.56M | 2.78M | 3.37M | 3.31M | 2.9M | |||||
Operating Income | -64.52M | -126M | -131M | -93.65M | 253M | |||||
Net Income | -66.15M | -126M | -127M | -78.96M | 275M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 28.63M | 27.36M | 26.58M | 60M | 434M | |||||
Total Assets | 324M | 348M | 248M | 358M | 745M | |||||
Interest Expense | -598K | - | - | - | - | |||||
Income Tax Expense | 1.3M | - | - | - | 4.22M | |||||
D&A | 2.56M | 2.78M | 3.37M | 3.31M | 2.9M | |||||
CAPEX | -471K | -1.1M | -795K | -609K | -1.36M | |||||
Net Income | -66.15M | -126M | -127M | -78.96M | 275M | |||||
EBT | -64.84M | -126M | -127M | -78.96M | 279M | |||||
Operating Income | -64.52M | -126M | -131M | -93.65M | 253M |
- Stock Market
- Equities
- PTGX Stock
- Financials Protagonist Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition